Subcutaneous anti-HER2 antibody formulations and uses thereof

Patent metadata

Field	Value
Publication number	US-9968676-B2
Application number	US-201615053217-A
Country	US
Kind code	B2
Filing date	Feb 25, 2016
Priority date	Jul 31, 2009
Publication date	May 15, 2018
Grant date	May 15, 2018

Abstract

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

First claim

What is claimed is:

1. A highly concentrated, stable liquid pharmaceutical composition of pharmaceutically active anti-HER2 antibody for subcutaneous injection comprising:
a. 100 to 150 mg/ml anti-HER2 antibody, wherein the anti-HER2 antibody is a combination of Trastuzumab and Pertuzumab;
b. 1 to 50±5% mM of a buffering agent providing a pH of 5.5±2.0;
c. 150 to 250±5% mM of a mixture of trehalose and sucrose as a first stabilizer and 5 to 15 mM methionine as a secondary stabilizer;
d. 0.01 to 0.08±5% (w/v) of a nonionic surfactant; and
e. 1,000 to 16,000 U/ml of at least one hyaluronidase enzyme.

2. The pharmaceutical composition of claim 1 comprising 120 mg/ml of the combination of Trastuzumab and Pertuzumab.

3. The pharmaceutical composition of claim 1 , comprising 1′500 U/ml to 12,000 U/ml of the hyaluronidase enzyme.

4. The pharmaceutical composition of claim 3 , comprising 2,000 U/ml of the hyaluronidase enzyme.

5. The pharmaceutical composition of claim 4 , wherein the hyaluronidase enzyme is recombinant human hyaluronidase, rHuPH20.

6. The pharmaceutical composition of claim 1 , wherein the buffering agent is a histidine buffer.

7. The pharmaceutical composition of claim 5 , wherein the histidine buffer is a histidine chloride buffer at a pH of 5.5±0.6.

8. The pharmaceutical composition of claim 6 , wherein the histidine chloride buffer has a pH of 5.5.

9. The pharmaceutical composition of claim 1 , wherein the nonionic surfactant is a polysorbate selected from the group consisting of polysorbate 20, polysorbate 80, and polyethylene-polypropylene copolymer.

10. The pharmaceutical composition of claim 9 , wherein the nonionic surfactant is polysorbate 20.

11. An injection device comprising the highly concentrated stable ready for use pharmaceutical composition of claim 1 .

12. A method of treating a disease or disorder which is amenable to treatment with an anti-HER2 antibody in a subject comprising administering to said subject a pharmaceutical composition according to claim 1 in an amount effective to treat said disease or disorder.

13. The method of claim 12 , wherein the disease is cancer.

14. The method of claim 13 , wherein the cancer is breast cancer.

15. The method of claim 14 , wherein the cancer is HER2 overexpressing breast cancer.

16. A kit comprising a vial containing the highly concentrated stable ready for use pharmaceutical composition of claim 1 and instructions for subcutaneous administration of the composition to a patient.

17. The kit of claim 16 further comprising an injection device for subcutaneous administration of the pharmaceutical composition to the patient.

Assignees

• Genentech Inc

Inventors

• Adler Michael
• Grauschopf Ulla
• Mahler Hanns-Christian
• Stauch Oliver Boris

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61K47/20

  containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids · CPC title

• A61K47/183

  Amino acids, e.g. glycine, EDTA or aspartame · CPC title

• A61K39/39591

  Stabilisation, fragmentation · CPC title